Physician profile
Michael E Lembach
NPI 1548207582
$1,274.65
in general payments reported to CMS, 2019-2025
12 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.24 · 2020: $48.42 · 2021: $35.29 · 2022: $164 · 2023: $238 · 2024: $334 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $267.06 | 2019-2025 | Precision7, Rocklatan, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $218.05 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $164.64 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $147.04 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $104.83 | 2023-2025 | Idosetr, Idose |
| Abbvie INC. | $94.63 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $72.75 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $53.93 | 2023-2025 | Miebo, Infuse, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.60 | 2019-2021 | |
| Dompe US, INC. | $45.74 | 2024 | Oxervate |
| Harrow Eye, LLC | $42.47 | 2024-2025 | Vevye |
| Rxsight INC | $13.91 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lembach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.